bioRxivImmunologyPreprint
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation
Abstract
Previous work has shown that innate immune sensing of tumors involves the host STING pathway, which leads to IFN-{beta} production, dendritic cell (DC) activation, and T cell priming against tumor antigens. This observation has led to the development of STING agonists as a potential cancer therapeutic. However, despite promising results in mouse studies using transplantable tumor models, clinical testing of STING agonists has shown activity in only a minority of patients. Thus, further study of innate immune pathways in anti-tumor immunity is paramount. Innate immune activation in response to a pathogen rarely occurs through stimulation of only one signaling pathway, and activating multiple innate immune pathways similar to a natural infection is one possible strategy to improve the efficacy of STING agonists. To test this, we performed experiments with the STING agonist DMXAA alone or in combination with several TLR agonists. We found that LPS + DMXAA induced significantly greater IFN-{beta} transcription than the sum of either agonist alone. To explain this synergy, we assayed each step of STING pathway signaling. LPS did not increase STING protein aggregation, IRF3 phosphorylation, or IRF3 nuclear translocation beyond what occurred with DMXAA alone. However, since the IFN-{beta} promoter also includes NF-{kappa}B binding sites, we additionally examined the NF-{kappa}B pathway. In fact, LPS increased the phosphorylation and nuclear translocation of the NF-{kappa}B subunit p65, and NF-{kappa}B signaling was required for the observed synergy. Intratumoral injection of suboptimal doses of LPS + DMXAA resulted in significantly improved tumor control of B16 melanoma in vivo compared to either agonist alone. Our results suggest that combinatorial signaling through TLR4 and STING results in optimal innate signaling via co-involvement of NF-{kappa}B and IRF3, and that combined engagement of these two pathways has therapeutic potential.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: differential expression
- approach: experimental assay
- Citations
- 4
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies
M. Danielson, C. J. Nicolai, … T. P. Burke·bioRxiv·Jan 30, 2024
- Context-dependent triggering of STING-interferon signaling by CD11b agonists supports anti-tumor immunity in mouse models and human cancer patients
X. Liu, G. D. Hogg, … D. DeNardo·bioRxiv·Mar 22, 2022
- Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes antitumour immunity in combination with radiotherapy
Malin Pedersen, Lisa C. Hubbard, … Kevin J Harrington·bioRxiv·Mar 25, 2026
- STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity
- STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity
Mélanie Girard, Tianning Yu, … Tania H. Watts·The Journal of ImmunologyPeer-reviewed·Jul 9, 2025
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses
B. Jneid, A. Bochnakian, … N. Manel·bioRxiv·Dec 1, 2021